Found: 53
Select item for more details and to access through your institution.
Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 1, p. e163, doi. 10.1016/j.clgc.2023.10.008
- By:
- Publication type:
- Article
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.
- Published in:
- 2015
- By:
- Publication type:
- journal article
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non--Small-Cell Lung Cancer: A Mini-Review.
- Published in:
- Clinical Lung Cancer, 2015, v. 16, n. 5, p. 334, doi. 10.1016/j.cllc.2015.03.004
- By:
- Publication type:
- Article
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
- Published in:
- Experimental Hematology & Oncology, 2017, v. 6, p. 1, doi. 10.1186/s40164-017-0089-y
- By:
- Publication type:
- Article
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors.
- Published in:
- Lung Cancer: Targets & Therapy, 2020, v. 11, p. 33, doi. 10.2147/LCTT.S239675
- By:
- Publication type:
- Article
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification.
- Published in:
- Lung Cancer: Targets & Therapy, 2019, v. 10, p. 21, doi. 10.2147/LCTT.S190403
- By:
- Publication type:
- Article
Dramatic response to alectinib in a lung cancer patient with a novel <em>VKORC1L1-ALK</em> fusion and an acquired ALK T1151K mutation.
- Published in:
- Lung Cancer: Targets & Therapy, 2018, v. 9, p. 111, doi. 10.2147/LCTT.S186804
- By:
- Publication type:
- Article
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.
- Published in:
- Lung Cancer: Targets & Therapy, 2018, v. 9, p. 45, doi. 10.2147/LCTT.S161738
- By:
- Publication type:
- Article
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
- Published in:
- AAPS Journal, 2020, v. 22, n. 6, p. N.PAG, doi. 10.1208/s12248-020-00514-4
- By:
- Publication type:
- Article
Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 3, p. e225394, doi. 10.1001/jamanetworkopen.2022.5394
- By:
- Publication type:
- Article
RET rearrangements are actionable alterations in breast cancer.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-07341-4
- By:
- Publication type:
- Article
Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
- Published in:
- 2017
- By:
- Publication type:
- Report
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00644-4
- By:
- Publication type:
- Article
Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
- Published in:
- Histopathology, 2024, v. 84, n. 7, p. 1224, doi. 10.1111/his.15168
- By:
- Publication type:
- Article
Evidence‐Based Development and Clinical Use of Precision Oncology Therapeutics.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 3, p. 440, doi. 10.1002/cpt.1967
- By:
- Publication type:
- Article
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
- Published in:
- BJU International, 2020, v. 125, n. 5, p. 739, doi. 10.1111/bju.15006
- By:
- Publication type:
- Article
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 7, p. 1778, doi. 10.1002/ijc.33447
- By:
- Publication type:
- Article
Identification of NTRK fusions in pediatric mesenchymal tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Genomic landscape of 891 RET fusions detected across diverse solid tumor types.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00347-2
- By:
- Publication type:
- Article
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
- Published in:
- NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00334-z
- By:
- Publication type:
- Article
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
- Published in:
- Head & Neck, 2017, v. 39, n. 3, p. E40, doi. 10.1002/hed.24634
- By:
- Publication type:
- Article
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.
- Published in:
- Cancer (0008543X), 2017, v. 123, n. 18, p. 3628, doi. 10.1002/cncr.30781
- By:
- Publication type:
- Article
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA.
- Published in:
- Oncology, 2020, v. 98, n. 12, p. 905, doi. 10.1159/000510241
- By:
- Publication type:
- Article
A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR.
- Published in:
- Oncology, 2019, v. 96, n. 2, p. 101, doi. 10.1159/000493322
- By:
- Publication type:
- Article
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
- Published in:
- Oncology, 2016, v. 91, n. 6, p. 348, doi. 10.1159/000449204
- By:
- Publication type:
- Article
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
- Published in:
- Oncologist, 2024, v. 29, n. 8, p. e984, doi. 10.1093/oncolo/oyae028
- By:
- Publication type:
- Article
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 8, p. 691, doi. 10.1093/oncolo/oyad178
- By:
- Publication type:
- Article
Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.
- Published in:
- Oncologist, 2022, v. 27, n. 11, p. 919, doi. 10.1093/oncolo/oyac115
- By:
- Publication type:
- Article
RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 6, p. 469, doi. 10.1002/onco.13679
- By:
- Publication type:
- Article
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
- Published in:
- Oncologist, 2020, v. 25, n. 1, p. e147, doi. 10.1634/theoncologist.2019-0244
- By:
- Publication type:
- Article
FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.
- Published in:
- Oncologist, 2019, v. 24, n. 11, p. 1462, doi. 10.1634/theoncologist.2019-0121
- By:
- Publication type:
- Article
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
- Published in:
- Oncologist, 2019, v. 24, n. 10, p. 1340, doi. 10.1634/theoncologist.2019-0034
- By:
- Publication type:
- Article
Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. 791, doi. 10.1634/theoncologist.2018-0334
- By:
- Publication type:
- Article
Hybrid Capture‐Based Genomic Profiling Identifies BRAF V600 and Non‐V600 Alterations in Melanoma Samples Negative by Prior Testing.
- Published in:
- Oncologist, 2019, v. 24, n. 5, p. 657, doi. 10.1634/theoncologist.2018-0271
- By:
- Publication type:
- Article
Hybrid Capture‐Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well‐Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
- Published in:
- Oncologist, 2018, v. 23, n. 7, p. 776, doi. 10.1634/theoncologist.2017-0493
- By:
- Publication type:
- Article
ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.
- Published in:
- Oncologist, 2017, v. 22, n. 12, p. 1444, doi. 10.1634/theoncologist.2016-0488
- By:
- Publication type:
- Article
Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.
- Published in:
- Oncologist, 2017, v. 22, n. 7, p. 774, doi. 10.1634/theoncologist.2016-0376
- By:
- Publication type:
- Article
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
- Published in:
- Oncologist, 2017, v. 22, n. 4, p. 416, doi. 10.1634/theoncologist.2016-0310
- By:
- Publication type:
- Article
Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
- Published in:
- Oncologist, 2017, v. 22, n. 3, p. 255, doi. 10.1634/theoncologist.2016-0279
- By:
- Publication type:
- Article
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
- Published in:
- Oncologist, 2016, v. 21, n. 11, p. 1306, doi. 10.1634/theoncologist.2016-0148
- By:
- Publication type:
- Article
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-ResponsiveALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
- Published in:
- Oncologist, 2016, v. 21, n. 6, p. 762, doi. 10.1634/theoncologist.2015-0497
- By:
- Publication type:
- Article
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 24, p. 4557, doi. 10.1002/cncr.33865
- By:
- Publication type:
- Article